Skip to content

Author

Ying-lei Gao

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Low-dose antiangiogenic multikinase inhibitor AL3810 synergizes with PD-1 blockade by reducing CSF1-driven MHC-IIint tumour-associated macrophages to optimize TIM-3+ CD8+ T-cell effector function.

BACKGROUND AND PURPOSE Antiangiogenic multikinase inhibitors (AAMKIs) with PD-1/PD-L1 blockade have been approved to treat certain solid tumours. Their synergy mechanisms remain largely unknown. AL3810 (lucitanib), a AAMKI in Phase II trials, has demonstrated clinical activity. We aim to elucidate the immune modulatory...

Kun Fang, Wen-Xin Zhang, Zi-Han Li et al. · 0 citations
Jul 2026

Discovery of Thiazolo[5,4-c]pyridine Derivatives as Novel Hematopoietic Progenitor Kinase 1 Inhibitors for Tumor Immunotherapy.

This new inhibitor exhibits potent HPK1 inhibition, high selectivity within the MAP4K family, along with improved metabolic properties and reduced hERG liability, and demonstrates robust monotherapy efficacy and synergizes with an anti-PD-1 antibody or an anti-PD-L1/IL-15 immunocytokine prodrug.

Ying Wang, Ye Yang, Yi-Ming Yu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.